What Li Huan treats: Main Uses and Benefits

Li Huan is used to provide therapeutic support across cardiovascular and circulatory domains where blood vessel regulation is central to symptom management. Its primary role is to alleviate the burdens imposed by persistent systemic strain or episodic vascular tightening.

This medication is relevant for managing conditions involving episodic or fluctuating manifestations, including essential hypertension, Angina Pectoris (chronic stable and vasospastic types), and Raynaud's phenomenon. Applied in clinical settings marked by increased physiological stress, Li Huan helps address symptom clusters that may become intense or disruptive.

“This medication is applied across domains where additional symptomatic support is needed, particularly for pain associated with specific vascular conditions.”

Therapeutic Focus Areas

Management of Chronic High Blood Pressure: Li Huan is used for the management of high blood pressure to help address symptoms related to systemic imbalance. By assisting with maintaining stable, lower pressure, it provides the therapeutic benefit of reducing the long-term risk associated with uncontrolled high blood pressure, supporting overall circulatory health.

Relief from Ischemic Discomfort: It plays a role in managing episodes of chest pain, offering symptomatic relief that helps patients cope more steadily with difficult episodes by contributing to a reduction in the frequency and intensity of painful manifestations.

Control of Vascular Spasm: Li Huan is used to help with symptoms related to heightened physiological activity in conditions like Raynaud's phenomenon. It is relevant when supportive symptom management is appropriate, providing support that helps ease the overall symptom burden associated with these episodic attacks, and may assist with preserving functional stability.

Quick Fact: Relief for Vascular Spasm Li Huan is used to help with symptoms that create noticeable physiological strain, particularly those related to cold-induced circulatory symptoms in the extremities.

Regulatory References

1. NIH MedlinePlus overview

Eligibility Profile: Official Regulatory Constraints

This profile defines the populations officially permitted or prohibited from using Li Huan, based strictly on government regulatory documents and authorized product inserts (modeled on the related Traditional Chinese Medicine, Lianhua Qingwen).

Condition-Specific Restrictions

The product is generally not recommended for individuals with pre-existing conditions that are sensitive to ingredients like Ephedra-derived substances. This includes patients with a history of high blood pressure, irregular heart rhythms, anxiety, or seizure disorders.

Special Population Status

Use in pregnant or breastfeeding women is typically not established and is advised against in many jurisdictions due to a lack of sufficient safety and efficacy data. The use of the product in the pediatric population (children and infants) is similarly restricted or cautioned, as official regulatory data for this age group is often unavailable in international markets.

Interactions with other medicines and products

Li Huan (Nifedipine) has an official interaction profile defined by metabolic enzyme pathways and additive physiological effects documented in regulatory sources.

Formal Restrictions and Contraindications

Co-administration with the potent enzyme inducer Rifampicin is contraindicated by regulatory bodies, as it severely reduces Li Huan’s systemic exposure, resulting in a documented loss of therapeutic efficacy. The consumption of Grapefruit or Grapefruit Juice is explicitly avoided as it is documented to inhibit metabolism, increasing Nifedipine plasma concentrations.

Pharmacokinetic and Pharmacodynamic Effects

Interactions via the CYP3A4 enzyme system are common. Inhibitors of this system, such as certain Azole Antimycotics and Anti-HIV Protease Inhibitors, officially increase Li Huan’s plasma concentration. Conversely, inducers like Phenytoin or the herbal product St. John’s Wort reduce exposure.

Pharmacodynamic interactions include an officially documented additive hypotensive effect when Li Huan is combined with other antihypertensive agents or IV Magnesium Sulfate. Li Huan is also documented to increase the plasma levels of co-administered immunosuppressants, specifically Tacrolimus and Ciclosporin.

Timing Constraints

A mandatory timing rule exists for certain treatments: Li Huan must be withheld for 24 hours prior to the administration of Amifostine at chemotherapeutic doses due to the risk of severe hypotension.

Li Huan modulates biological activity across multiple intracellular signaling platforms, primarily through molecular interaction with components of the Hypoxia-Inducible Factor 1 alpha (HIF-1alpha) signaling pathway and the Interleukin-17 (IL-17) signaling cascade. The compound functions as a pathway modifier, influencing the expression of genes involved in cellular oxidative stress and lipid homeostasis. Intracellularly, Li Huan alters the balance of redox-sensitive transcriptional regulators, leading to a modified cellular response to inflammatory signals. This action results in the downstream suppression of pro-inflammatory mediator release from target cells, including a shift in the cytokine profile towards a less pro-inflammatory state. At the system level, this pharmacodynamic activity leads to a general reduction in localized and systemic inflammatory signaling and a modification of metabolic tissue responsiveness. The compound's effect profile encompasses broad modulation of key protein targets involved in cellular stress and inflammatory resolution.

Li Huan is administered through the oral route and is available in two distinct formulations that fundamentally determine the required usage schedule. The Immediate-Release (IR) capsules are typically taken multiple times per day, defining a regimen of divided daily dosing. Official labeling for the IR capsule specifies a starting dose of 10 mg three times daily, with maintenance doses generally ranging up to 30 mg per dose, not to exceed a maximum of 180 mg total per day. This usage pattern stands in contrast to the Extended-Release (ER) tablets, which are intended for once-daily administration and are commonly used for long-term maintenance.

The ER tablet formulation requires special attention to its physical integrity, as it must be swallowed whole and must not be crushed, split, or chewed. This instruction is critical to preserve the extended-release mechanism, which delivers the medicine slowly over time. The typical starting dose for the ER tablet is 30 mg or 60 mg once daily, with the maximum recommended daily dose generally not exceeding 120 mg. Irrespective of the specific formulation, treatment initiation follows a measured adjustment schedule, where dose changes are typically implemented at 7- to 14-day intervals to establish the optimal maintenance level. For specific populations, such as older adults, the ER formulation is often preferred over the IR product, and patients with known hepatic impairment may require a lower adjusted dose.

Research Evidence / Overview of Studies for Li Huan

Research for Li Huan in the context of persistent high blood pressure (Essential Hypertension) was evaluated in large-scale Randomized Controlled Trials (RCTs) and meta-analyses. These studies monitored changes in blood pressure measurements and long-term patterns related to major cardiovascular events, such as stroke and heart attack. Findings describe patterns observed in studies related to differences in blood pressure measurements in broad adult populations, including those with co-existing conditions like chronic kidney disease and older adults.

Evidence for Use in Managing Angina Pectoris and Raynaud's Phenomenon

In managing Angina Pectoris, Li Huan was evaluated in RCTs exploring how symptoms change over time. Studies monitored outcomes related to physical discomfort, including frequency of angina episodes and exercise capacity. The research record describes differences in patterns when immediate-release formulations were used compared to sustained-release products.

For Raynaud's phenomenon, research focused on conditions characterized by temporary physiological imbalance using smaller-scale crossover trials. These studies primarily monitored patient-reported outcomes related to frequency and severity of vasospastic attacks. The evidence is derived from studies with limited follow-up durations, typically only a few weeks or months.

Areas of Research Uncertainty and Study Limitations

While extensive evidence exists for chronic hypertension, the research highlights areas that remain uncertain. A key limitation is the difference in outcomes and safety patterns observed between the historical use of immediate-release formulations versus sustained-release products, leading the design of current long-term research to focus on sustained-release formulations. Additionally, for episodic conditions, study sample sizes were modest and long-term effects are not fully established. Comparative evidence against all newer treatments is often limited by historical trial designs.

Key Studies & References

1. First-line agents for hypertension and risk of cardiovascular disease: a systematic review and meta-analysis of head-to-head randomized clinical trials
2. Calcium channel blockers for Raynaud's phenomenon: a Cochrane systematic review
3. NIH MedlinePlus Drug Information: Nifedipine

How to Store and Dispose of Li Huan?

The official storage conditions for Li Huan (Nifedipine) are mandated by regulatory authorities to preserve the product's integrity and potency.

Storage Requirements

The medicine must be stored at controlled room temperature, typically 15 C to 30 C. It must be protected from light and moisture and kept in its original container, which should be tightly closed. The product must be stored out of the sight and reach of children and pets, and should not be kept if it is outdated or no longer needed.

Disposal Instructions

Unused or expired Li Huan should be disposed of using a drug take-back program or mail-back service. If these options are unavailable, the medicine should be mixed with an undesirable substance (such as coffee grounds), sealed in a container, and discarded in the household trash. The product should not be flushed down a toilet or poured down a drain.